Search results
Results From The WOW.Com Content Network
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith ...
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines .
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term
Rotarix (human rotavirus vaccine, live attenuated) Shingrix (for Zoster Vaccine Recombinant, Adjuvanted) Synflorix (pneumococcal polysaccharide conjugate vaccine (adsorbed)) Twinrix (for combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen)) Typherix (typhoid vaccine (purified polysaccharide ...
GlaxoSmithKline (GSK) closed the most recent trading day at $43.56, moving -0.32% from the previous trading session.